Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE

Brown, J. R., Eichhorst, B., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Jurczak, W., Zhou, K., Šimkovič, M., Mayer, J., Gillespie-Twardy, A., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., Osterborg, A., Yimer, H. A., … Shadman, M. (2024). Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE. Blood Journal. https://doi.org/10.1182/blood.2024024667

Authors:

Jennifer R. Brown

Barbara Eichhorst

Nicole Lamanna

Susan O’Brien

Constantine S. Tam

Lugui Qiu

Wojciech Jurczak

Keshu Zhou

Martin Šimkovič

Jiřı́ Mayer

Amanda Gillespie-Twardy